GH Research is developing several 5-MeO-DMT based therapeutic mechanisms (inhalation and IV) for the treatment of several disorders (including TRD).
The products the company is developing (GH001 and GH002) are in phase I & II and preclinical studies at the moment.
In April 2021, GH Research a total of $125 million in a Series B round. GH Research is registered under the ticker NASDAQ: GHRS. Their stock opened with $16.00 in its Jun 24, 2021, IPO after which they raised an additional $184 million.
- Johannes Ramaekers – Scientific Advisor
- GH Research Announces Closing of $125 Million Oversubscribed Series B Financing (Psilocybin Alpha, April 2021)
B2B B2C Pharmaceutical Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates